MAP2K1 and MAP3K1 mutations in langerhans cell histiocytosis

Genes Chromosomes and Cancer

Volumn 54, Issue 6, 2015, Pages 361-368

  Nelson, David S ^a   van Halteren, Astrid ^b   Quispel, Willemijn T ^b   van den Bos, Cor ^c   Bovée, Judith V M G ^b   Patel, Bhumi ^a   Badalian Very, Gayane ^a,d   van Hummelen, Paul ^a   Ducar, Matthew ^a   Lin, Ling ^a   Macconaill, Laura E ^a,d   Egeler, R Maarten ^e   Rollins, Barrett J ^a,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN VARIANT; RAS PROTEIN; TRAMETINIB; ANTINEOPLASTIC AGENT; MAP2K1 PROTEIN, HUMAN; MAP3K1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; PYRIDONE DERIVATIVE; PYRIMIDINONE DERIVATIVE;

AMINO TERMINAL SEQUENCE; ARTICLE; CLINICAL ARTICLE; DELETION MUTANT; DNA SEQUENCE; ENZYME ACTIVITY; GENE DELETION; GERMLINE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LANGERHANS CELL HISTIOCYTOSIS; MUTAGENESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SOMATIC MUTATION; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE KINASE 1; MUTATION; PHOSPHORYLATION; PYRIDONES; PYRIMIDINONES; SIGNAL TRANSDUCTION;

EID: 84928060838     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22247     Document Type: Article

References (27)

1. Allen CE, Li L, Peters TL, Leung HC, Yu A, Man TK, Gurusiddappa S, Phillips MT, Hicks MJ, Gaikwad A, Merad M, McClain KL. 2010. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol 184:4557-4567.
2. Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M, Fleming MD, Rollins BJ. 2010. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 116:1919-1923.
3. Badalian-Very G, Vergilio JA, Fleming M, Rollins BJ. 2013. Pathogenesis of Langerhans cell histiocytosis. Annu Rev Pathol 8:1-20.
4. Bechan GI, Egeler RM, Arceci RJ. 2006. Biology of Langerhans cells and Langerhans cell histiocytosis. Int Rev Cytol 254:1-43.
5. Berres ML, Lim KP, Peters T, Price J, Takizawa H, Salmon H, Idoyaga J, Ruzo A, Lupo PJ, Hicks MJ, Shih A, Simko SJ, Abhyankar H, Chakraborty R, Leboeuf M, Beltrao M, Lira SA, Heym KM, Bigley V, Collin M, Manz MG, McClain K, Merad M, Allen CE. 2014. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med 211:669-683.
6. Brown NA, Furtado LV, Betz BL, Kiel MJ, Weigelin HC, Lim MS, Elenitoba-Johnson KS. 2014. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood 124:1655-1658.
7. Cancer Genome Atlas Network. 2012. Comprehensive molecular portraits of human breast tumours. Nature 490:61-70.
8. Chakraborty R, Hampton OA, Shen X, Simko SJ, Shih A, Abhyankar H, Lim KP, Covington KR, Trevino L, Dewal N, Muzny DM, Doddapaneni H, Hu J, Wang L, Lupo PJ, Hicks MJ, Bonilla DL, Dwyer KC, Berres ML, Poulikakos PI, Merad M, McClain KL, Wheeler DA, Allen CE, Parsons DW. 2014. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood 124:3007-3015.
9. Egeler RM, van Halteren AG, Hogendoorn PC, Laman JD, Leenen PJ. 2010. Langerhans cell histiocytosis: fascinating dynamics of the dendritic cell-macrophage lineage. Immunol Rev 234:213-232.
10. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwn ica-Worms D, Stuart JM, Wilson RK, Mardis ER. 2012. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486:353-360.
11. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, Hatton C, Chopra R, Oberholzer PA, Karpova MB, MacConaill LE, Zhang J, Gray NS, Sellers WR, Dummer R, Garraway LA. 2009. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 106:20411-20416.
12. Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN, Dickerson SH, Laquerre SG, Liu L, Gilmer TM. 2012. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 11:909-920.
13. Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, Cluzel P, Drier A, Hervier B, Benameur N, Besnard S, Donadieu J, Amoura Z. 2013. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 121:1495-1500.
14. Hirai S, Noda K, Moriguchi T, Nishida E, Yamashita A, Deyama T, Fukuyama K, Ohno S. 1998. Differential activation of two JNK activators, MKK7 and SEK1, by MKN28-derived nonreceptor serine/threonine kinase/mixed lineage kinase 2. J Biol Chem 273:7406-7412.
15. Kansal R, Quintanilla-Martinez L, Datta V, Lopategui J, Garshfield G, Nathwani BN. 2013. Identification of the V600D mutation in Exon 15 of the BRAF oncogene in congenital, benign langerhans cell histiocytosis. Genes Chromosomes Cancer 52:99-106.
16. Lange-Carter CA, Pleiman CM, Gardner AM, Blumer KJ, Johnson GL. 1993. A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf. Science 260:315-319.
17. Nelson DS, Quispel W, Badalian-Very G, van Halteren AG, van den Bos C, Bovee JV, Tian SY, Van Hummelen P, Ducar M, MacConaill LE, Egeler RM, Rollins BJ. 2014. Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood 123:3152-3155.
18. Sahm F, Capper D, Preusser M, Meyer J, Stenzinger A, Lasitschka F, Berghoff AS, Habel A, Schneider M, Kulozik A, Anagnostopoulos I, Mullauer L, Mechtersheimer G, von Deimling A. 2012. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood 120:e28-e34.
19. Satoh T, Smith A, Sarde A, Lu HC, Mian S, Trouillet C, Mufti G, Emile JF, Fraternali F, Donadieu J, Geissmann F. 2012. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. PLoS ONE 7:e33891.
20. Siow YL, Kalmar GB, Sanghera JS, Tai G, Oh SS, Pelech SL. 1997. Identification of two essential phosphorylated threonine residues in the catalytic domain of Mekk1. Indirect activation by Pak3 and protein kinase C. J Biol Chem 272:7586-7594.
21. Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, Jane-Valbuena J, Friedrich DC, Kryukov G, Carter SL, McKenna A, Sivachenko A, Rosenberg M, Kiezun A, Voet D, Lawrence M, Lichtenstein LT, Gentry JG, Huang FW, Fostel J, Farlow D, Barbie D, Gandhi L, Lander ES, Gray SW, Joffe S, Janne P, Garber J, MacConaill L, Lindeman N, Rollins B, Kantoff P, Fisher SA, Gabriel S, Getz G, Garraway LA. 2014. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med 20:682-688.
22. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA. 2011. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29:3085-3096.
23. Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, Abaan OD, Davis SR, Kreitman RJ, Meltzer PS. 2014. High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet 46:8-10.
24. Widmann C, Gerwins P, Johnson NL, Jarpe MB, Johnson GL. 1998. MEK kinase 1, a substrate for DEVD-directed caspases, is involved in genotoxin-induced apoptosis. Mol Cell Biol 18:2416-2429.
25. Willman CL, Busque L, Griffith BB, Favara BE, McClain KL, Duncan MH, Gilliland DG. 1994. Langerhans'-cell histiocytosis (histiocytosis X)-A clonal proliferative disease. N Engl J Med 331:154-160.
26. Yan M, Dai T, Deak JC, Kyriakis JM, Zon LI, Woodgett JR, Templeton DJ. 1994. Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1. Nature 372:798-800.
27. Yu RC, Chu C, Buluwela L, Chu AC. 1994. Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet 343:767-768.